| Ascend Branson West Llc | |
|
18020 Business 13 Suite E Branson West MO 65737 | |
| (417) 272-3352 | |
| (417) 272-1518 |
| Full Name | Ascend Branson West Llc |
|---|---|
| Speciality | Clinic/center - Dental |
| Location | 18020 Business 13, Branson West, Missouri |
| Authorized Official Name and Position | Derek Magers (DENTIST/CO-OWNER) |
| Authorized Official Contact | 4178873100 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Ascend Branson West Llc Po Box 2045 Branson West MO 65737 Ph: (417) 272-3352 | Ascend Branson West Llc 18020 Business 13 Suite E Branson West MO 65737 Ph: (417) 272-3352 |
| NPI Number | 1811641749 |
|---|---|
| Provider Enumeration Date | 02/09/2022 |
| Last Update Date | 02/09/2022 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811641749 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QD0000X | Clinic/center - Dental | (* (Not Available)) | Primary |
News Archive
Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc.. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.
Children with prominent front teeth, colloquially known as buck teeth, often require orthodontic work to straighten their teeth and improve both their bite and appearance.
There are found genes that have been identified to be associated with obsessive compulsive disorder (OCD). These genes have been found to alter the circuitry of the brain in a manner that could lead to OCD. These genetic links also point to the fact why OCD sometimes runs in families. The study is published in the latest issue of Nature Communications.
An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England Journal of Medicine. The now published results were previously presented at the American Diabetes Association's 71st Scientific Sessions in San Diego, California, USA, on June 28, 2011.
Delivering life-saving drugs across the blood-brain barrier (BBB) might become a little easier thanks to a new report published in the November 2014 issue of The FASEB Journal.
› Verified 7 days ago